Journal
MEDCHEMCOMM
Volume 9, Issue 6, Pages 963-968Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c8md00068a
Keywords
-
Funding
- TAKTIC Translational Kinase Tumour Inhibitor discovery Consortium FP7-SME-2012 grant [315746]
Ask authors/readers for more resources
NF-kappa B-inducing kinase (NIK), an oncogenic drug target that is associated with various cancers, is a central signalling component of the non-canonical pathway. A blind screening process, which established that amino pyrazole related scaffolds have an effect on IKKbeta, led to a hit-to-lead optimization process that identified the aminopyrazole 3a as a low M selective NIK inhibitor. Compound 3a effectively inhibited the NIK-dependent activation of the NF-kappa B pathway in tumour cells, confirming its selective inhibitory profile.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available